Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.

Authors:
M Gérard H de Boysson R Morello N Martin-Silva A-C Leroux A Dumont G Maigné J Boutemy K Khoy D Mariotte T Lobbedez A Aouba S Deshayes

Scand J Rheumatol 2022 Jan 20:1-13. Epub 2022 Jan 20.

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Objective: Few comparative data exist on early infections secondary to remission-induction therapy (RIT) with rituximab (RTX) versus cyclophosphamide (CYC) in newly diagnosed anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients. We compared and analysed the rates and predictors of severe infection in such patients within the first 6 months following RIT.

Method: From the Caen University Hospital databases, we included all consecutive adults newly diagnosed with ANCA-positive granulomatosis with polyangiitis or microscopic polyangiitis between January 2006 and December 2019. We compared rates of survival without severe infection and survival without infections of any severity within 6 months of RIT and used a multivariate Cox analysis to identify predictors of infection.

Results: We included 145 patients, 27 in the RTX and 118 in the CYC group. Patients in the RTX group more frequently had pneumococcal vaccination (p < 0.01) and creatinine < 150 µmol/L; other characteristics were comparable between the two groups. Overall, 37 severe infections and 65 infections of any severity were recorded. Rates of survival without severe infection were similar in both groups (p = 0.69), but survival without infections of any severity was lower in the RTX group (p = 0.005). In multivariate analysis, risk factors at diagnosis for severe infections included chronic urinary tract disease, dialysis, and absence of trimethoprim-sulfamethoxazole prophylaxis (p < 0.01 each).

Conclusions: Within 6 months of RIT, rates of survival without severe infection were similar in newly diagnosed ANCA-positive AAV patients treated with RTX or CYC, but survival rates without infections of any severity appeared to be lower with RTX treatment.

Download full-text PDF

 Source
http://dx.doi.org/10.1080/03009742.2021.2001929DOI Listing
January 2022

Publication Analysis

Top Keywords

patients rtx
8
newly diagnosed
8
remission-induction therapy
8
anti-neutrophil cytoplasmic
8
severe infection
8
patients
5
survival severe
4
predictors severe
4
compared rates
4
rates predictors
4
analysed rates
4
rates survival
4
compared analysed
4
infection survival
4
patients compared
4
aav patients
4
vasculitis aav
4
survival infections
4
anca-associated vasculitis
4
antibody anca-associated
4

Keyword Occurance

Similar Publications

Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.

Authors:
Jie Lin Binbin Xue Jia Li Ruofan Zhu Juyuan Pan Zhibo Chen Xu Zhang Xiang Li Junhui Xia

Front Neurol 2022 6;13:891064. Epub 2022 May 6.

Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Background: Several studies have reported the efficacy and safety of rituximab (RTX) and mycophenolate mofetil (MMF) in neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the efficacy and safety of long-term use of low-dose RTX and MMF in Chinese patients with NMOSD.

Methods: We retrospectively reviewed data from patients with NMOSD in our hospital. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Rituximab-induced serum sickness in a girl with nephrotic syndrome.

Authors:
Yuka Kimura Kyoko Kiyota Mayo Ikeuchi Kazuhito Sekiguchi Kenji Ihara

CEN Case Rep 2022 May 20. Epub 2022 May 20.

Department of Pediatrics, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593, Japan.

Rituximab (RTX) has been used to treat B cell lineage lymphoma/leukemia or autoimmune or autoinflammatory disorders. RTX therapy has been extensively applied to cases of frequently relapsing nephrotic syndrome (FRNS) and steroid-dependent nephrotic syndrome. Rituximab-induced serum sickness (RISS) has been recognized as a rare severe type-3 hypersensitivity reaction in patients treated with RTX. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic.

Authors:
Katarzyna Łosińska Mateusz Wilk Are Hugo Pripp Mariusz Korkosz Glenn Haugeberg

Sci Rep 2022 May 18;12(1):8283. Epub 2022 May 18.

Division of Rheumatology, Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway.

To explore the long-term drug effectiveness and survival of reference rituximab (ref-RTX)-treated rheumatoid arthritis (RA) patients in an ordinary outpatient clinic. Second, we explored baseline predictors of drug effectiveness and survival, and third, we clarified reasons for stopping treatment. RA patients treated with ref-RTX between 2006 and 2020 in Norway were examined and monitored using recommended measures for disease activity and patient-reported outcomes (PROs). Read More

View Article and Full-Text PDF
May 2022
Similar Publications

A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study.

Authors:
Maryam Tavakoli Chaleshtori Ziba Farajzadegan Mansour Salesi

Eur J Rheumatol 2022 Apr;9(2):88-92

Department of Internal Medicine, Isfahan University of Medical Sciences, School of Medicine, Isfahan, Iran.

Objective: Granulomatosis with polyangiitis (GPA), formerly known as Wegner's granulomatosis, is a rare vasculitic syndrome classified under Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA)-associ- ated vasculitides, which is fatal if untreated. The mainstay of treatment consists of immunosuppression using a combination of corticosteroids with either rituximab (RTX) or cyclophosphamide (CYC). We aimed to compare the 4-year clinical outcomes between patients with GPA receiving CYC and RTX as remission induction. Read More

View Article and Full-Text PDF
April 2022
Similar Publications

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.

Authors:
Maurizio Benucci Arianna Damiani Francesca Li Gobbi Barbara Lari Valentina Grossi Maria Infantino Mariangela Manfredi

Immunol Res 2022 May 11. Epub 2022 May 11.

Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Via Torregalli, 3, 50143, Florence, Italy.

Only case reports and small clinical series report the effects of booster vaccination with BNT162b2 in patients with rheumatoid arthritis (RA). We studied 200 patients with RA in clinical remission evaluated with the DAS28. All patients were vaccinated for SARS CoV-2 with the BNT162b2 mRNA vaccine. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}